Cochrane · systematic review · CD001245
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
Germans, MR, Dronkers, WJ, Baharoglu, MI, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
StrokeAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 40%High 3 · 60%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Poor outcome | RR 1.03 [0.94, 1.13] | 5 studies · 2359 participants | High |
All cause mortality | RR 1.02 [0.9, 1.16] | 11 studies · 2717 participants | High |
Rebleeding | RR 0.65 [0.47, 0.91] | 11 studies · 2717 participants | Moderate Downgraded: inconsistency, indirectness |
Delayed cerebral ischemia | RR 1.27 [1, 1.62] | 7 studies · 2484 participants | Moderate Downgraded: inconsistency, indirectness |
Hydrocephalus | RR 1.09 [0.99, 1.2] | 6 studies · 1992 participants | High |